Calcium carbonate + Vitamin D3

Generic Medicine Info
Indications and Dosage
Calcium deficiency, Vitamin D deficiency
Adult: Available preparations:
Ca carbonate 1,500 mg (equivalent to 600 mg elemental Ca) and vitamin D3 10 mcg (equivalent to 400 IU) conventional tab
Ca carbonate 1,500 mg (equivalent to 600 mg elemental Ca) and vitamin D3 10 mcg (equivalent to 400 IU) chewable tab
Ca carbonate 1,500 mg (equivalent to 600 mg elemental Ca) and vitamin D3 10 mcg (equivalent to 400 IU) effervescent tab
Ca carbonate 1,250 mg (equivalent to 500 mg elemental Ca) and vitamin D3 11 mcg (equivalent to 440 IU) effervescent granules for oral solution

Prophylaxis and treatment: Dosage must be individualised according to the patient’s deficit or daily maintenance requirements. As 1,500 mg/400 IU conventional and chewable tab: 1 tab bid, preferably 1 tab in the morning and 1 tab in the evening. As 1,500 mg/400 IU effervescent tab: 1 tab bid dissolved in approx 200 mL of water, preferably 1 tab in the morning and 1 tab in the evening. As 1,250 mg/440 IU effervescent granules: 1 or 2 sachets daily, dissolved in a glass of water. Dosage recommendations may vary among individual products and between countries (refer to detailed product guideline).
Elderly: Same as adult dose.
Should be taken with food.
Nephrolithiasis, nephrocalcinosis, hypervitaminosis D, hypercalcaemia, hypercalciuria; diseases leading to hypercalcaemia or hypercalciuria (e.g. bone metastases or other malignant bone diseases, myeloma, primary hyperparathyroidism). Severe renal failure and impairment.
Special Precautions
Patient with achlorhydria, hypoparathyroidism; risk factor for hypercalcaemia (e.g. sarcoidosis), history of kidney stones, high tendency to calculus formation. Immobilised patients with osteoporosis. Mild to moderate renal impairment. Elderly. Pregnancy and lactation.
Adverse Reactions
Significant: Hypercalcaemia, Milk-alkali syndrome, constipation, bloating, flatulence.
Gastrointestinal disorders: Nausea, abdominal pain, diarrhoea.
Immune system disorders: Hypersensitivity reactions.
Renal and urinary disorders: Hypercalciuria.
Skin and subcutaneous tissue disorders: Rarely, rash, pruritus, urticaria.
Monitoring Parameters
Monitor serum Ca levels and renal function (e.g. serum creatinine).
Symptoms: Hypercalcaemia characterised by anorexia, thirst, vomiting, nausea, abdominal pain, muscle weakness, fatigue, mental disturbances, polyuria, polydipsia, nephrocalcinosis, bone pain, renal calculi, and cardiac arrhythmia and coma in severe cases. High amounts of Ca ingestion may cause Milk-alkali syndrome, irreversible renal damage and soft calcification. Management: Discontinue use of Ca carbonate and vitamin D3 treatment. Empty contents of the stomach in patients with impaired consciousness, rehydrate, and based on the severity may consider combined or isolated treatment with bisphosphonates, loop diuretics, corticosteroids and calcitonin. Closely monitor serum electrolytes, renal function and diuresis.
Drug Interactions
May enhance the arrhythmogenic effects of cardiac glycosides.
Calcium carbonate: Increased risk of hypercalcaemia with thiazide diuretics. May decrease the gastrointestinal absorption of bisphosphonates, Na fluoride, quinolones, tetracyclines, levothyroxine, Fe, zinc and strontium. Ca absorption may be reduced by systemic corticosteroids.
Vitamin D3: Decreased effects with phenytoin, barbiturates, rifampicin, glucocorticosteroids. May reduce gastrointestinal absorption with colestyramine or paraffin oil.
Food Interaction
Food may increase Ca absorption. Bran, foods high in oxalates, or whole grain cereals may decrease Ca absorption.
Description: Ca and vitamin D3 administration counteracts the rise of PTH that is caused by Ca deficiency and increased bone resorption.
Calcium carbonate is used as a supplementary source of Ca to help prevent or decrease the rate of bone loss in osteoporosis. It also acts as an antacid by neutralising gastric acidity resulting in increased gastric and duodenal pH.
Vitamin D3 is a fat-soluble sterol essential for the proper regulation of Ca and phosphate homeostasis, bone metabolism and mineralisation.
Synonym: vitamin D3: colecalciferol, cholecalciferol.
Absorption: Calcium carbonate: Absorbed from the gastrointestinal tract, predominantly in the duodenum.
Vitamin D3: Well-absorbed from the gastrointestinal tract (in the presence of bile).
Distribution: Enters breastmilk.
Calcium carbonate: Primarily in bones and teeth. Plasma protein binding: Approx 40%, to albumin.
Metabolism: Calcium carbonate: Converted into Ca chloride by gastric acid.
Vitamin D3: Metabolised in the liver by vitamin D 25-hydroxylase via hydroxylation into active metabolite, 25-hydroxycolecalciferol; further converted in the kidneys by vitamin D 1-hydroxylase to form the active 1,25-dihydroxycolecalciferol (calcitriol).
Excretion: Via faeces and urine.
Chemical Structure

Chemical Structure Image
Calcium carbonate

Source: National Center for Biotechnology Information. PubChem Database. Calcium carbonate, CID=10112, (accessed on Jan. 21, 2020)

Chemical Structure Image
Vitamin D3

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 5280795, Cholecalciferol. Accessed Feb. 22, 2021.

Store below 25°C. Protect from light and moisture.
MIMS Class
Calcium/with Vitamins
Accrete D3 Film-Coated Tablets (Internis Pharmaceuticals Ltd). MHRA. Accessed 01/02/2021.

Adcal-D3 Chewable Tablets (Kyowa Kirin Limited). MHRA. Accessed 01/02/2021.

Adcal-D3 Dissolve 1500mg/400IU Effervescent Tablets (Kyowa Kirin Limited). MHRA. Accessed 01/02/2021.

Anon. Calcium and Vitamin D. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 01/02/2021.

Buckingham R (ed). Calcium Carbonate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 01/02/2021.

Buckingham R (ed). Vitamin D Substances. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 01/02/2021.

Cacit 500 mg/440 IU, Effervescent Granules for Oral Solution in Sachet (Teva NI Limited). MHRA. Accessed 01/02/2021.

Joint Formulary Committee. Colecalciferol with Calcium Carbonate. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 01/02/2021.

Kalcipos-D 500 mg/ 800 IU Film-Coated Tablets (Mylan Products Ltd.). MHRA. Accessed 01/02/2021.

Disclaimer: This information is independently developed by MIMS based on Calcium carbonate + Vitamin D3 from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
  • Morecal
  • Revital Calcium D3
  • Zecal-D3
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in